Guggenheim Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Neutral 62.2%

Neg 0% Neu 62.2% Pos 0%

Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $7.